At the core of CD4 Therapeutics is our lead asset, Tregalizumab - a highly innovative monoclonal antibody designed to selectively activate regulatory T-cells (Tregs). Tregs are crucial for maintaining immune balance, and Tregalizumab’s ability to restore immune regulation holds the promise to disrupt the current treatment paradigms in dermatology and oncology by addressing severe conditions like oral Lichen Planus (oLP) and acute Graft-vs-Host Disease (aGvHD). Both diseases represent significant global health burdens with limited treatment options. CD4 Therapeutics aims to deliver life-changing therapies to patients who currently have little to no disease-modifying solutions.

What sets Tregalizumab apart is its:

• Proven safety profile, demonstrated across nearly 700 patients.

• Early clinical proof-of-concept, positioning it as a potential game-changer for T-cell mediated disorders.

Our preclinical data strongly support its potential to change the standard of care in two high-impact indications:

• Oral Lichen Planus (oLP) – a lesser-known but highly underserved dermatological condition. Over 3,000,000 moderate-to-severe patients suffer from this pre-cancerous condition. As the only Treg targeting approach with promising efficacy data in dermatology to date, Tregalizumab has the potential to be a 1st in class compound with a disruptive therapeutic profile providing a dual benefit for oLP patients - Disease Control and Cancer Prevention.

• Acute Graft-versus-Host-Disease (aGvHD) – with Orphan Drug Designation from the FDA, aGvHD presents a significant opportunity. Despite recent advancements, there remains a 50% non-responder rate to current therapies, leaving a substantial unmet need. Top KOLs are rallying behind the potential of Tregalizumab to offer a much-needed therapeutic breakthrough.